Abilify is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Abilify appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, abilify is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, abilify displays an antagonist profile at the 5-HT2A receptor. Abilify has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
Abilify is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Abilify is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Abilify acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Abilify. Abilify’s antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Abilify’s antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.